BioXcel Therapeutics (BTAI) News Today $0.34 +0.03 (+8.12%) (As of 12/20/2024 05:45 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period BioXcel Therapeutics amends credit agreement, issues new warrantsNovember 23, 2024 | investing.comBioxcel Therapeutics Restructures Credit and Strengthens LeadershipNovember 23, 2024 | markets.businessinsider.comBioXcel Prices New OfferingNovember 23, 2024 | baystreet.caBioXcel Therapeutics prices 5.6M shares at 48c in public offeringNovember 23, 2024 | markets.businessinsider.comBioXcel announces common stock and warrants offering, no amount givenNovember 22, 2024 | markets.businessinsider.comBioXcel Therapeutics Announces Pricing of $7.0 Million Public OfferingNovember 22, 2024 | globenewswire.comBioXcel Therapeutics Announces Proposed Public OfferingNovember 21, 2024 | globenewswire.comBioXcel Therapeutics Reports Q3 2024 Financial ResultsNovember 16, 2024 | markets.businessinsider.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q3 2024 Earnings Call TranscriptNovember 16, 2024 | msn.comBioXcel Therapeutics Reports Third Quarter 2024 Financial ResultsNovember 14, 2024 | finance.yahoo.comBioXcel Therapeutics advances Phase 3 trials of BXCL501November 13, 2024 | markets.businessinsider.comWhat's Next: BioXcel Therapeutics's Earnings PreviewNovember 13, 2024 | benzinga.comBioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024November 8, 2024 | globenewswire.comBioXcel Therapeutics to Present at ThinkEquity ConferenceOctober 29, 2024 | globenewswire.comBioXcel Therapeutics price target lowered to $5 from $7 at H.C. WainwrightOctober 22, 2024 | markets.businessinsider.comBioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress DisorderOctober 15, 2024 | globenewswire.comBioXcel Therapeutics (NASDAQ:BTAI) Stock, Short Interest ReportSeptember 28, 2024 | benzinga.comBioXcel ends commercial support for Igalmi as focus turns to neuro candidateSeptember 19, 2024 | msn.comBioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationSeptember 19, 2024 | globenewswire.comBioXcel Therapeutics executive sells shares worth $238September 18, 2024 | in.investing.comFMR LLC's Strategic Reduction in BioXcel Therapeutics Inc SharesSeptember 12, 2024 | finance.yahoo.comBioxcel Therapeutics Earns Buy Rating on Promising Clinical Trials and Market PotentialSeptember 7, 2024 | markets.businessinsider.comBioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaSeptember 5, 2024 | globenewswire.comBioXcel Therapeutics Inc (BX2.BE)August 29, 2024 | sg.finance.yahoo.comBioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth ConferenceAugust 7, 2024 | finance.yahoo.comBuy Rating Maintained for Bioxcel Therapeutics Amid Positive Performance and Growth ProspectsAugust 7, 2024 | markets.businessinsider.comBioXcel Therapeutics Reports Second Quarter 2024 Financial ResultsAugust 6, 2024 | markets.businessinsider.comBioXcel Therapeutics GAAP EPS of -$0.21 beats by $0.57, revenue of $1.1M in-lineAugust 6, 2024 | msn.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Rises By 8.7%BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a significant growth in short interest in June. As of June 30th, there was short interest totalling 1,620,000 shares, a growth of 8.7% from the June 15th total of 1,490,000 shares. Based on an average trading volume of 588,800 shares, the days-to-cover ratio is presently 2.8 days.July 16, 2024 | marketbeat.comBioXcel Therapeutics Announces Preliminary Estimated Unaudited Second Quarter Net Revenues from Sales of IGALMI™ (dexmedetomidine) Sublingual FilmJuly 16, 2024 | globenewswire.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Given Average Rating of "Hold" by BrokeragesShares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) have been given an average recommendation of "Hold" by the seven brokerages that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a hold recommendation and three have assigned a buy reJune 8, 2024 | marketbeat.comVimal Mehta Sells 126,014 Shares of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) StockJune 7, 2024 | insidertrades.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) CEO Vimal Mehta Sells 126,014 SharesBioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) CEO Vimal Mehta sold 126,014 shares of the stock in a transaction that occurred on Tuesday, June 4th. The stock was sold at an average price of $1.63, for a total value of $205,402.82. Following the transaction, the chief executive officer now owns 7,811,515 shares in the company, valued at $12,732,769.45. The transaction was disclosed in a filing with the SEC, which is accessible through this link.June 6, 2024 | marketbeat.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest Up 8.7% in MayBioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a significant growth in short interest in May. As of May 15th, there was short interest totalling 1,630,000 shares, a growth of 8.7% from the April 30th total of 1,500,000 shares. Based on an average trading volume of 584,400 shares, the days-to-cover ratio is presently 2.8 days.June 1, 2024 | marketbeat.comBioXcel Therapeutics to Present at Jefferies Global Healthcare ConferenceMay 28, 2024 | globenewswire.comBioXcel Therapeutics Announces Oral and Poster Presentations at the 2024 American Society of Clinical Psychopharmacology (ASCP) Annual MeetingMay 21, 2024 | globenewswire.comHold Rating on Bioxcel Therapeutics Amid Growth Potential and Financial UncertaintiesMay 14, 2024 | markets.businessinsider.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Short Interest UpdateBioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a significant decrease in short interest in the month of April. As of April 30th, there was short interest totalling 1,500,000 shares, a decrease of 28.2% from the April 15th total of 2,090,000 shares. Based on an average trading volume of 1,440,000 shares, the short-interest ratio is currently 1.0 days.May 13, 2024 | marketbeat.comBioXcel Therapeutics (NASDAQ:BTAI) Releases Earnings Results, Misses Expectations By $0.19 EPSBioXcel Therapeutics (NASDAQ:BTAI - Get Free Report) announced its earnings results on Thursday. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.19). BioXcel Therapeutics had a negative return on equity of 890.63% and a negative net margin of 12,974.86%. The company had revenue of $0.58 million during the quarter, compared to the consensus estimate of $0.42 million. During the same period in the prior year, the firm posted ($1.84) earnings per share.May 10, 2024 | marketbeat.comBullish Outlook: Bioxcel Therapeutics’ Revenue Surge and Promising Clinical Trials Fuel Buy RatingMay 10, 2024 | markets.businessinsider.comBioXcel Therapeutics First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | finance.yahoo.comBioXcel Therapeutics, Inc. (NASDAQ:BTAI) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comQ1 2024 BioXcel Therapeutics Inc Earnings CallMay 10, 2024 | finance.yahoo.comBTAI Stock Earnings: BioXcel Therapeutics Misses EPS, Beats Revenue for Q1 2024May 9, 2024 | investorplace.comBioXcel Therapeutics GAAP EPS of -$0.87 misses by $0.12, revenue of $0.58M misses by $0.05MMay 9, 2024 | msn.comBioXcel Therapeutics Reports First Quarter 2024 Financial ResultsMay 9, 2024 | globenewswire.comBioXcel Therapeutics Q1 2024 Earnings PreviewMay 8, 2024 | msn.com2 Contracts Traded for 20JUN24 BTI PHY DN Single Stock Dividend Neutral FutureMay 1, 2024 | msn.comShort Interest in BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Declines By 16.1%BioXcel Therapeutics, Inc. (NASDAQ:BTAI - Get Free Report) was the recipient of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 2,090,000 shares, a decline of 16.1% from the March 31st total of 2,490,000 shares. Based on an average daily volume of 1,510,000 shares, the short-interest ratio is presently 1.4 days.April 29, 2024 | marketbeat.comHold Rating on Bioxcel Therapeutics Amid Strategic and Clinical Trial UncertaintiesApril 26, 2024 | markets.businessinsider.com Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Crypto’s hidden gem + greatest crypto bull run in history = $$$? (Ad)You don’t actually want to buy Bitcoin this time around. That’s because there’s a better way to take advantage of this new bull market… One market expert calls it Crypto’s Hidden Gem And it’s a new way that has given folks like you and me the chance to see bigger and faster moves than the traditional way of buying Bitcoin… That means if you’ve stayed away from Bitcoin and crypto because it's confusing or seems risky… This is a much safer and better approach to ride this years’ crypto bull run. Because believe it or not… The 2024 crypto bull run is one you DON’T want to miss. Click Here to get the full details about Crypto’s Hidden Gem BTAI Media Mentions By Week BTAI Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BTAI News Sentiment▼-1.000.60▲Average Medical News Sentiment BTAI News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BTAI Articles This Week▼32▲BTAI Articles Average Week Get BioXcel Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BTAI and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Connect Biopharma News Spero Therapeutics News Aadi Bioscience News Mural Oncology News Invivyd News Kronos Bio News Immix Biopharma News Immuneering News Shattuck Labs News AlloVir News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BTAI) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BioXcel Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BioXcel Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free BTAI Stock Alerts